嚢胞性線維症(CF)治療の世界市場2016-2026:嚢胞性線維症膜貫通調節因子(CFTR)モジュレータ、タンパク質転写モジュレータ、膵酵素生成物(PEP)...市場調査レポートについてご紹介

【英文タイトル】Global Cystic Fibrosis Therapeutics Market 2016-2026-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Global Cystic Fibrosis Market Overview
1.2 Why You Should Read This Report
1.3 Structure of the Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Primary Research
1.7.2 Secondary Research
1.7.3 Market Evaluation & Forecasting Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated visiongain Reports
1.10 About visiongain

2. Introduction to the Cystic Fibrosis Market
2.1 An Overview of Cystic Fibrosis
2.2 Genetics Associated With Cystic Fibrosis
2.2.1 CFTR Chromosome Location
2.2.2 CFTR Mutations
2.2.3 Inheritance Pattern
2.3 New-born Screening for Cystic Fibrosis
2.4 Signs and Symptoms
2.4.1 Respiratory Inflammation and Infections
2.4.2 Gastrointestinal Tract Symptoms
2.4.3 Fertility and Reproduction Related Issues
2.5 Diagnosis
2.5.1 Sweat Testing
2.5.2 Nasal Potential Measurements Voltage
2.5.3 Genotyping
2.5.4 Ancillary Testing
2.6 Treatment
2.6.1 Gene Therapy
2.6.2 Symptomatic Treatment
2.6.2.1 Respiratory Care
2.6.2.2 Inhaled Bronchodilators
2.6.2.3 Airway Clearance
2.6.2.4 Antibiotics
2.6.2.5 Lung Transplant
2.6.2.6 Other Treatments
2.7 Prognosis
2.8 Quality of Life
2.9 Epidemiology
2.9.1 Epidemiology Trends in the US
2.9.1.1 Age Distribution of Cystic Fibrosis Patients in the US
2.10 Epidemiology Trends in Europe
2.10.1 Age Distribution of Cystic Fibrosis Patients in Europe
2.11 Epidemiology Trends in Canada
2.12 Epidemiology Trends in RoW
2.13 Epidemiology Trends of F 508 Del Mutations

3. Global Cystic Fibrosis Market 2016-2026
3.1 Cystic Fibrosis Regional Markets 2016-2026
3.1.1 US Cystic Fibrosis Market Forecast 2016-2026
3.1.1 Cost per Patient per Year (US)
3.1.2 Price Increase of Cystic Fibrosis Drugs YoY (US)
3.1.3 Patients Treated by Various Drugs (US)
3.1.4 Patient Share vs Market Share of Top Products (US)
3.2 Europe Cystic Fibrosis Market Forecast 2016-2026
3.3 RoW Cystic Fibrosis Market Forecast 2016-2026
3.3.1 Cystic Fibrosis Japan Market
3.4 Cystic Fibrosis Regional Market Forecast 2016-2026

4. Cystic Fibrosis market – By Pharmaceutical class 2016-2026
4.1 Cystic Fibrosis market – CFTR Modulators 2016-2026
4.1.1 Orkambi (Vertex Pharmaceuticals) market – CFTR Modulators 2016-2026
4.1.2 Kalydeco (Vertex Pharmaceuticals) market – CFTR Modulators 2016-2026
4.1.3 VX-661 + ivacaftor (Royalty Pharma) market – CFTR Modulators 2016-2026
4.1.4 Second corrector/VX-661/ivacaftor (Vertex Pharmaceuticals) market – CFTR Modulators 2016-2026
4.1.5 Cross Comparison of CFTR Modulators Forecast 2016-2026
4.2 Cystic Fibrosis market – Protein Transcription Modulators 2016-2026
4.2.1 Pulmozyme (Roche) market – Protein Transcription Modulators 2016-2026
4.2.2 QR-010 (ProQR Therapeutics) – Protein transcription Modulators 2016-2026
4.2.3 Translarna (PTC Therapeutics) market – CFTR Modulators 2016-2026
4.2.4 Cross Comparison of Protein Transcription Modulators Forecast 2016-2026
4.3 Cystic Fibrosis market – Ceron (AbbVie), Pancreatic enzyme product (PEP) 2016-2026
4.4 Cystic Fibrosis market – Other Therapies 2016-2026
4.4.1 Cayston (Gilead Science) Market Forecast 2016-2026
4.4.2 TOBI (Novartis) Market Forecast 2016-2026
4.5 Cross Comparison of Pharmacological Class Forecast in CF 2016-2026

5. Timeline of Product Launches, Patent analysis and Deal analysis for Key Therapies
5.1 Timeline of US Product Launches – Key Therapies
5.2 Timeline of Europe Product Launches – Key Therapies
5.3 Timeline of Japan Product Launches – Key Therapies
5.4 Patent analysis in Cystic Fibrosis – Key Therapies
5.4.1 Patent analysis of Launched Products – Key Therapies
5.4.2 Patent analysis of Phase 3 Products – Key Therapies
5.4.3 Patent analysis of Phase 2 Products – Key Therapies
5.4.4 Patent analysis of Phase 1 Products – Key Therapies
5.4.5 Patent analysis of pre-clinical and research stage products – Key Therapies
5.5 Deal analysis in Cystic Fibrosis – Key Therapies

6. Product Profiles in Cystic Fibrosis – Key Therapies
6.1 Orkambi (Vertex Pharmaceuticals) Product Profile
6.2 Kalydeco (Vertex Pharmaceuticals) Product Profile
6.3 Pulmozyme (Roche) Product Profile
6.4 Translarna (PTC Therapeutics) Product Profile
6.5 Tezacaftor (Vertex Pharmaceuticals) Product Profile
6.6 Ivacaftor and tezacaftor (Vertex Pharmaceuticals) Combination Product Profile

7. Company Profiles
7.1 Vertex Company Profile
7.1.1 Vertex Company Overview
7.1.2 Vertex Projects Overview
7.1.3 Vertex Recent Deals
7.1.4 Key Product sales (2010-2020)
7.2 Roche Company Profile
7.2.1 Roche Company Overview
7.2.2 Roche Projects Overview
7.2.3 Roche Recent Deals
7.2.4 Roche Key Product sales
7.3 AbbVie Company Profile
7.3.1 AbbVie Company Overview
7.3.2 AbbVie Projects Overview
7.3.3 AbbVie Recent Deals
7.3.4 AbbVie Key Product Sales
7.4 Gilead Sciences Company Profile
7.4.1 Gilead Company Overview
7.4.2 Gilead Projects Overview
7.4.3 Gilead Recent Deals
7.4.3 Gilead Key Product Sales
7.5 Novartis Company Profile
7.5.1 Novartis Company Overview
7.5.2 Novartis Projects Overview
7.5.3 Novartis Recent Deals
7.5.3 Novartis Key Product Sales

8. Qualitative Analysis of the Cystic Fibrosis Market
8.1 Strengths of the Cystic Fibrosis Market
8.2 Weaknesses of the Cystic Fibrosis Market
8.3 Opportunities for the Cystic Fibrosis Market
8.4 Threats for the Cystic Fibrosis Market
8.5 Political Factors Influencing the Cystic Fibrosis Market
8.6 Economical Factors Influencing the Cystic Fibrosis Market
8.7 Social Factors Influencing the Cystic Fibrosis Market
8.8 Technological Factors Influencing the Cystic Fibrosis Market

9. Conclusions
9.1 Cost of Therapies in Cystic Fibrosis
9.2 Patient vs Market Share Trends in Cystic Fibrosis
9.3 Global Cystic Fibrosis Market Trends from 2016 to 2026
9.4 Geographical trends of Cystic Fibrosis Market
9.5 Cystic Fibrosis Market as per Pharmacological Class

10. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form


【レポート販売概要】

■ タイトル:嚢胞性線維症(CF)治療の世界市場2016-2026:嚢胞性線維症膜貫通調節因子(CFTR)モジュレータ、タンパク質転写モジュレータ、膵酵素生成物(PEP)
■ 英文:Global Cystic Fibrosis Therapeutics Market 2016-2026-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies
■ 発行日:2016年11月
■ 調査会社:visiongain
■ 商品コード:VGAIN61206
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。